{"nctId":"NCT00685919","briefTitle":"Peripheral Dopamine in Postural Tachycardia Syndrome","startDateStruct":{"date":"2008-05","type":"ACTUAL"},"conditions":["Postural Tachycardia Syndrome","Orthostatic Intolerance"],"count":32,"armGroups":[{"label":"Carbidopa then Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Carbidopa","Drug: Placebo"]},{"label":"Placebo then Carbidopa","type":"EXPERIMENTAL","interventionNames":["Drug: Carbidopa","Drug: Placebo"]}],"interventions":[{"name":"Carbidopa","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients diagnosed with POTS by the Vanderbilt Autonomic Dysfunction Center based on the following stringent criteria: 1) history of daily orthostatic symptoms for at least 6 months; 2) increase in heart rate (HR) of at least 30 bpm with standing or a standing HR of at least 120 bpm; 3) absence of orthostatic hypotension (defined as a fall in blood pressure (BP)\\>20/10 mm Hg); and 4) absence of conditions, such as dehydration, substantial weight loss, or systemic illnesses, that could provoke orthostatic intolerance\n* Upright plasma NE at least 600 pg/mL in patients\n* Non-smoking\n* Free of medications with the potential to influence BP\n* Able and willing to provide informed consent -\n\nExclusion Criteria:\n\n* Overt cause for postural tachycardia (such as acute dehydration)\n* Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or screening results\n* Positive urine b-hcg pregnancy test\n* Evidence of cardiac structural disease (by clinical examination or prior echocardiogram)\n* Hypertension defined as a BP\\>145/95 (off medications) or need for antihypertensive medications\n* Evidence of significant conduction system delay (QRS duration \\>120 ms) on electrocardiogram\n* Inability to give, or withdraw, informed consent","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"24 Hour Urinary Sodium Excretion During Treatment Normalized to Creatinine","description":"Urine was collected for 24hr during treatment. Urinary volume was measured and the urine was analyzed for sodium and creatinine concentrations. Total amounts of sodium and creatinine excreted over the 24 hr were calculated and results expressed as ratio of sodium:creatinine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":"29"},{"groupId":"OG001","value":"132","spread":"38"},{"groupId":"OG002","value":"137","spread":"30"},{"groupId":"OG003","value":"154","spread":"31"}]}]}]},{"type":"SECONDARY","title":"Systolic Blood Pressure Measured at 8 Hours After the Last Dose of Placebo or Carbidopa","description":"Systolic blood pressure was measured once using a Dinamap non-invasive oscillometric blood pressure monitor, 2-4 hours after lunch and after at least 30 minutes of resting supine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":"4"},{"groupId":"OG001","value":"101","spread":"8"},{"groupId":"OG002","value":"102","spread":"9"},{"groupId":"OG003","value":"101","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Plasma Catecholamines (Norepinephrine) After the Last Dose of Placebo or Carbidopa","description":"Blood samples were collected while resting supine for at least 30 minutes and 2 to 4 hours after lunch. For catecholamine measurements, blood was collected in chilled vacuum tubes with EDTA. Plasma was separated and stored with added reduced glutathione (Amersham International PLC) at -70°C until the assay. Plasma catecholamines were measured by a method that involves batch alumina extraction followed by high-performance liquid chromatography (HPLC) for separation with electrochemical detection and quantification.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":"46"},{"groupId":"OG001","value":"181","spread":"100"},{"groupId":"OG002","value":"278","spread":"84"},{"groupId":"OG003","value":"245","spread":"70"}]}]}]},{"type":"SECONDARY","title":"Plasma Catecholamines (DOPA) After the Last Dose of Placebo or Carbidopa","description":"Blood samples were collected while resting supine for at least 30 minutes and 2 to 4 hours after lunch. For catecholamine measurements, blood was collected in chilled vacuum tubes with EDTA. Plasma was separated and stored with added reduced glutathione (Amersham International PLC) at -70°C until the assay. Plasma catecholamines were measured by a method that involves batch alumina extraction followed by high-performance liquid chromatography (HPLC) for separation with electrochemical detection and quantification.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1813","spread":"463"},{"groupId":"OG001","value":"20297","spread":"9509"},{"groupId":"OG002","value":"2104","spread":"700"},{"groupId":"OG003","value":"25680","spread":"13825"}]}]}]},{"type":"SECONDARY","title":"24 Hour Urinary Catecholamine (DOPA) Excretion During Treatment Normalized to Creatinine","description":"Urine was collected over 24 hours during treatment. The urinary volume was measured and the urine was analyzed for creatinine and catecholamines. Total amounts of creatinine and catecholamines were calculated and the results are expressed as catecholamine:creatinine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.024","spread":"0.014"},{"groupId":"OG001","value":"0.283","spread":"0.194"},{"groupId":"OG002","value":"0.026","spread":"0.015"},{"groupId":"OG003","value":"0.385","spread":"0.156"}]}]}]},{"type":"SECONDARY","title":"24 Hour Urinary Catecholamine (Dopamine) Excretion During Treatment Normalized to Creatinine","description":"Urine was collected over 24 hours during treatment. The urinary volume was measured and the urine was analyzed for creatinine and catecholamines. Total amounts of creatinine and catecholamines were calculated and the results are expressed as catecholamine:creatinine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.208","spread":"0.061"},{"groupId":"OG001","value":"0.035","spread":"0.015"},{"groupId":"OG002","value":"0.24","spread":"0.081"},{"groupId":"OG003","value":"0.038","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Supine Plasma Renin Activity 2 Hours After the Last Dose of Placebo or Carbidopa","description":"Blood samples were collected while resting supine for at least 30 minutes and 1 1/2 to 2 hours after breakfast. Samples were processed and sent to the Vanderbilt Clinic Laboratory for assay.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.153","spread":"0.926"},{"groupId":"OG001","value":"1.033","spread":"0.529"},{"groupId":"OG002","value":"1.544","spread":"1.02"},{"groupId":"OG003","value":"1.878","spread":"1"}]}]}]},{"type":"SECONDARY","title":"Plasma Sodium After the Last Dose of Placebo or Carbidopa","description":"Blood samples were collected while resting supine for at least 30 minutes and 2 to 4 hours after lunch. Samples were processed and sent to the Vanderbilt Clinical Laboratory for assay.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":"1.9"},{"groupId":"OG001","value":"138","spread":"1.9"},{"groupId":"OG002","value":"139","spread":"2.2"},{"groupId":"OG003","value":"138","spread":"2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":17},"commonTop":["Head rush","Lightheadedness","Vertigo","Nausea"]}}}